Dr Khurum Khan is a research-active consultant who trained in medical oncology at the Northern Ireland Cancer Centre and Royal Marsden NHS Foundation Trust London. After working as a locum consultant at Royal Marsden for 18 months, Dr Khan took a substantive consultant position in gastrointestinal oncology at UCLH. He also attends North Middlesex University Hospital (NMUH), where he's the clinical lead of carcinoma of unknown primary (CUP).
He is actively involved in translational research and has presented and lectured in international conferences and public forums respectively. Dr Khan published several high-impact papers in peer-reviewed journals including Science, Cancer Discovery, Cancer Cell, Gut, Gastroenterologist, Clinical Cancer Research, Oncogene, Oncologist, BMC Cancer, British Medical Journal (BMJ) and British Journal of Cancer. He has served as an expert member of the National Research and Ethics Committee.
Dr Khan has also played an active role in improving the educational experience of the junior doctors nationally. He writes questions for MRCP(UK) and medical oncology exams, and remains part of the national medical oncology recruitment panel.
Dr Khan studied mechanisms of response and resistance to targeted therapies in advanced colorectal cancer and gained an MD(Res) degree under supervision of Professor David Cunningham at the Institute of Cancer Research and the Royal Marsden Hospital. He was involved in setup and conduct of large multicentre academic and translational studies from the time that he spent in full-time research, which included working as trial physician for phase II/III studies in early and advanced gastrointestinal cancers.
In collaboration with Professor Cunningham, Dr Khan secured funding from industry to run an academic phase II study of a multikinase inhibitor in metastatic refractory colorectal cancer. He also wrote a successful application for NIHR portfolio adoption of this study. His main research interests involve stratification of therapies in patients with gastroinetsinal malignancies, by setting up studies of clinical and translational relevance.
Woolston A*, Khan K.H*, Spain G*, et al. Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer. Accepted by Cancer Cell in April 2019
Khan K.H, Rane J, Cunningham D, Chau I, Rao S, Watkins D, Starling N, Kalaitzaki E, Foster M, Braconi C, Valeri N, Gerlinger M, and Chau I. Efficacy and cardiotoxic safety profile of Raltitrexed in Fluorouracil pre-treated or high-risk cardiac patients with GI malignancies- A large single-centre experience. Clinical Colorectal Cancer. 2019;18(1):64-71.
Anandappa G, Lampis A, Cunningham D, Khan K.H, et al. MicroRNA 31-3p expression and benefit from anti-EGFR inhibitors in metastatic colorectal cancer patients enrolled in the prospective phase II PROSPECT-C trial. Clinical Cancer Research. 2019; Apr 5. Pii: clincanres. 3769.2018. doi: 10.1158/1078-0432.CCR-18-3769.
Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K.H, et al. CEA Expression Heterogeneity and Plasticity Confer Resistance to the CEA-Targeting Bispecific Immunotherapy Antibody Cibisatamab (CEA-TCB) in Patient-Derived Colorectal Cancer Organoids.J Immunother Cancer. 2019; 15;7(1):101.
Khan K.H, Cunningham D, Werner B, et al. Forecasting the evolution of resistance to targeted treatment in metastatic colorectal cancer using longitudinal matched tissue and liquid biopsies in a prospective clinical trial. Cancer Discovery. 2018; 8(10):1270-1285.
Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K.H, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018; 359(6378): 920-926.
Khan K.H, Rata M, Cunningham D, et al. “Radiological and circulating biomarkers of response to Regorafenib in treatment-refractory metastatic colorectal cancer patients in a PROSPECTive phase II study(PROSPECT-R)”. GUT 2018; 67(8):1484-1492 .
Khan K.H, Athauda A, Aitken K, et al. Survival Outcomes in Asymptomatic Patients with Normal Conventional Imaging but Raised CEA Levels in Colorectal Cancer Following PET-CT Imaging. Oncologist. 2016; 21(12): 1502-1508.
Khan K.H, Wong M, Rihawi K, et al. Hyperglycaemia and PI3K, AKT and mTOR inhibitors in phase I trials: incidence, predictive factors and management. Oncologist. 2016; 21(7): 855-60.
Khan K.H, Cunningham D, Peckitt C, et al. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the Pancreatic cancer Erbitux, Radiotherapy and UFT (PERU) trial. Oncotarget. 2016; 7(11): 12672-12681.Khan K.H, Yap T, Ring et al. Phase I trials in older patients with advanced solid tumours. Br J Cancer. 2016; 114(3): 262-268.
Khan K.H, Cunningham D, Chau I. Targeting Angiogenic Pathway in Colorectal Cancer: Complexities, Challenges and Future Directions. Curr Drug Targets. 2016; 18(1): 56-71
Smyth E, Khan K.H, and Cunningham D. AREG and EREG as Predictive Biomarkers for RAS Wild-Type Colorectal Cancer Treated With Panitumumab: A Fresh Approach to an Old Puzzle. JAMA Oncology. 2016; 2(5):578-579
Khan K.H, Peckitt C, Sclafani F, et al. Prognostic factors and treatment outcomes in patients with small bowel adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience. BMC Cancer. 2015;15(1):15.
Tolcher A, Khan K.H, Ong M, et al. Antitumor activity in RAS-driven tumours by blocking AKT and MEK: Proof of concept preclinical and clinical data. Clin Cancer Res. 2015; 21(4): 739-748.
Roulstone V, Khan K.H, Pandha H, et al. Phase I trial of cyclophoshamide as immune modulator for optimising oncolytic reovirus delivery to solid tumors. Clin Cancer Res. 2015; 21(6): 1305-1312.
Moorcraft S, Khan K.H, Peckitt C, et al. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma (PDA); clinical outcomes and prognostic factors, The Royal Marsden (RM) experience. Clin Colorectal Cancer. 2014; 13(4): 232-238.
Khan K.H, Wale A, Brown G, Chau I. Colorectal cancer with liver metastases: chemotherapy, surgical resection first or palliation alone? World journal of gastroenterology. 2014; 20(35): 12391-12406.
Khan K.H, Ang JE, Starling N, et al. Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. Gastric Cancer. 2014; 17(4): 621-629.
Khan K.H, Blanco C.B, L R Molife. Cancer Therapeutics: Targeting the Apoptotic Pathway. Crit Rev Oncol and Haematol. 2014; 90(3); 200-219.
Khan K.H, Yap T.A, Yan L, and Cunningham D. Targeting the PI3K-AKT-mTOR signalling network in cancer. C Journal of Cancer. 2013; 32(5), 253-265.